News
Weight Loss In a Pill Will Make Eli Lilly a $1 Trillion Stock
Pharmaceutical giant Eli Lilly (LLY) surged 14% last week to $840 per share following positive Phase 3 trial results for its oral weight-loss drug, orforglipron. With a market cap of $796 billion, LLY is the world’s most valuable healthcare company, and its trajectory suggests it could reach $1,000 per share or more by year-end 2025.
13h
Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...
Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...
Let's look at why this news could be a game-changer for Eli Lilly and its stock.
Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...
Eli Lilly's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor. Click ...
WISH-TV on MSN10h
Eli Lilly spearheads global initiative to protect wildlife using synthetic alternativesEli Lilly and Company is leading a global effort to protect wildlife by shifting away from horseshoe crab blood and using a ...
Eli Lilly and Co. (LLY) emerged as a beacon of optimism last week in a market filled with uncertainty and volatility. Shares soared over 14% ...
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback